Entity

Time filter

Source Type

Guildford, United Kingdom

ReNeuron Group | Entity website

C. Hicks, L ...


ReNeuron Group | Entity website

Using our unique and scaleable stem cell technologies, we have created a pipeline of commercially focused stem cell therapy candidates addressing significant areas of unmet medical need. These therapeutic candidates are based around two core stem cell assets, our CTX neural cell line and our human retinal progenitor cells (hRPC) ...


The trial will involve CTXcells being administered by means of an injection into the brain 2to 12 months after a stroke episode (believed to be a suitable treatment window for efficacy), with each patient being monitored for 12 months after treatment. The trial will initially recruit 21 patients ...


ReNeuron Group | Entity website

The Audit Committee normally meets twice a year and has responsibility for, amongst other things, planning and reviewing the annual report and accounts and interim statements and involving, where appropriate, the external auditors, the Committee also approves external auditors fees and ensures auditor independence as well as focusing on compliance with legal requirements and accounting standards. It is also responsible for ensuring that an effective system of internal controls is maintained ...


ReNeuron Group | Entity website

Retinitis pigmentosais a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying. Pre-clinical studies carried out in disease models by the our academic collaborators have demonstrated that, when transplanted into the retina, our retinal progenitor cell technology has the potential to preserve existing photoreceptors, potentially reducing or halting further deterioration of vision ...

Discover hidden collaborations